BACKGROUND

Hepatitis C is a serious health problem with high prevalence rates, being the leading cause of liver transplantation. The development of well tolerated and highly effective direct active antivirals (DAAs) for hepatitis C virus (HCV) dramatically changed the therapeutic landscape.

PURPOSE

To assess the effectiveness of sofosbuvir/daclatasvir (SOF+DCV) compared to sofosbuvir/ledipasvir (SOF/LDV) used for the treatment of the hepatitis C virus genotype-3 infection.

MATERIAL AND METHODS

Retrospective and observational study between April 2015 and January 2016.

Inclusion criteria:
- Patients with HCV genotype-3 infection treated with SOF/LDV±Ribavirin (RBV) or with SOF+DCV during study period.

Outcomes collected:
- Demographics: age and sex.
- Clinical data: basal viral load (VL), METAVIR score: F0-F4, Liver transplant, HIV co-infection
- SVR at week 12 (SVR12), defined as HCV RNA titres lower than 15 IU/mL. Previous treatments for HCV.
- Data were collected from the medical records of patients.

RESULTS

Treatment with SOF/LDV±RBV: 20 patients were included (65% male) with mean age of 53.05±9.05 years. Patients were treated 12 weeks. According to METAVIR score: F4 (cirrhosis) (45%), F3 (35%), F2 (15%), F1 (5%). 10% of patients were HIV-coinfected, 15% had a liver transplant and 30% were pretreated with RBV/peginterferon. 45% of patients had an initial VL>800,000UI/ml.

Treatment with SOF+DCV: 20 patients (85% male) were included with mean age of 53.05±9.05 years. Patients were treated 12 weeks. According to METAVIR score: F4 (cirrhosis) 50%, F3 (20%), F2 (15%), F1 (10%). HIV-coinfected patients 45%, pretreated with RBV/peginterferon 25% and 30% had basal VL>800,000UI/ml.

CONCLUSION

Treatment with SOF+DCV seems to be more effective in our study. This matches the upper SVR12 rate achieved in ALLY-3 for SOF+DCV compared with results obtained in ELECTRON-2 for SOF/LDV in genotype 3, although the sample size and different baseline characteristics of the patients could be influencing these results.

ACKNOWLEDGEMENTS

No conflict of interest

juanparcardele@telefonica.net